Last reviewed · How we verify

NCT05659992

Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Completed Phase 2 Last updated 8 November 2024
What this trial tests

Phase 2 trial testing azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte in Acute Myeloid Leukemia in 30 participants. Completed in 14 August 2024.

Timeline
25 December 2022
Primary endpoint
14 August 2023
14 August 2024

Quick facts

Lead sponsorChinese PLA General Hospital
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date25 December 2022
Primary completion14 August 2023
Estimated completion14 August 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Adults 14 to 75, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with CACAG regimen in the treatment of newly diagnosed acute myeloid leukemia.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, et al · · 2023 · cited 22× · PMID 37071328 · DOI 10.1007/s44228-023-00041-x
  2. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
    Costa RGA, Silva SLR, Dias IRSB, Oliveira MS, et al · · 2023 · cited 16× · PMID 37031536 · DOI 10.1016/j.redox.2023.102692
  3. Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.
    Liu Q, Yang J, Lv L, Zhang X, et al · · 2025 · cited 1× · PMID 40079007 · DOI 10.3389/fimmu.2025.1525110
  4. A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
    Yang J, Liu Q, Zhang X, Jing Y, et al · · 2025 · cited 1× · PMID 39986194 · DOI 10.1016/j.intimp.2025.114268
  5. The role of m6A RNA methyltransferase METTL3 in drug resistance mechanisms in acute myeloid leukemia.
    Prajapati S, Jyotishi C, Patel M, Gupta R. · · 2026 · PMID 41615563 · DOI 10.1007/s44313-026-00123-8

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05659992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing